Find a study
Studies of GLP-1, incretin, and related peptide medications for weight and metabolic health.
16 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Obesity / overweight
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Testing how fasting and briefly stopping GLP-1 medicines changes stomach food
📍 Altasciences Clinical LA, Inc. · Cypress, CA · Get directions →
The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.
- Obesity / overweight
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
Testing a skin patch delivery of semaglutide versus a shot in people with obesity
📍 Celerion Clinical Research · Tempe, AZ · Get directions →
VX-201-101 is a first-in-human Phase 1 clinical study evaluating VX-201, a needle-free microneedle (MN) array patch (MAP) that delivers semaglutide through the skin as an alternative to subcutaneous (SC) injection.
- Kidney disease
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
Testing how a diabetes medicine in the bloodstream changes in kidney disease
📍 Floridian Clinical Research, LLC · Miami Lakes, FL · +1 more US site · Get directions →
The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants. The study drug will be administered subcutaneously (SC) (under the skin).
- Obesity / overweight
A Study to Evaluate ALN-2232 in Participants With Obesity
Testing a weight-loss drug in people with obesity for safety and how it works
📍 Clinical Trial Site · Mount Royal, · Get directions →
The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity
- Obesity / overweight
A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
Testing the safety and how the body absorbs a nasal spray in adults with obesity
📍 Frontage Clinical Services, Inc. · Secaucus, NJ · Get directions →
The specific aim of this study is to examine the Safety, Tolerability and Pharmacokinetic of Semaglutide Nasal Spray compared with placebo and positive control in Adult Overweight or Obese Participants.
- Obesity / overweight
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
Testing how weight-loss medicines affect metabolism compared with diet
📍 Advent Health-Res Inst · Orlando, FL · +1 more US site · Get directions →
In this study we will be looking into how CagriSema influences metabolism (the process by which food is used to supply energy for the body) compared to a diet. CagriSema is a new investigational medicine.
- Obesity / overweight
Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity
Testing how maridebart cafraglutide changes how birth control pills are absorbed
📍 Fortrea Clinical Research Unit - Daytona Beach · Daytona Beach, FL · +2 more US sites · Get directions →
The primary objective of the trial is to evaluate the effect of maridebart cafraglutide on the pharmacokinetics (PK) of a combined oral contraceptive (COC) in postmenopausal female participants living with overweight or obesity.
- Kidney disease
BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
Testing a vaccine to prevent Epstein-Barr virus cancer in transplant patients
📍 Ohio State University Comprehensive Cancer Center · Columbus, OH · Get directions →
This phase 1B trial tests the safety, side effects and best dose of rh-Hsc70- BZLF1 peptide complex (OSU-2131) with Stimulon (Trademark) QS-21 and evaluates how well it works in preventing Epstein-Barr virus (EBV) infection and related cancers in healthy volunteers and patients awaiting a solid organ transplant. Currently, patients who receive an organ transplant receive immune suppression therapy which can make it harder for the body to fight infections.
- Obesity / overweight
Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents
Studying how teens’ bodies respond to weight-loss surgery, with and without semaglutide
📍 Childrens Hospital Colorado · Aurora, CO · Get directions →
The study plans to learn more about what happens to the body after bariatric surgery in people 12 to 24 years old. The study aims to understand why people respond differently to bariatric surgery and how to define success beyond weight loss alone.
- Obesity / overweight
Tirzepatide in Obesity-Driven Endometrial Cancer
Testing tirzepatide’s effect on the uterine lining in people with endometrial cancer and obesity
📍 Lineberger Comprehensive Cancer Center · Chapel Hill, NC · Get directions →
LCCC2415 examines the antiproliferative effect of tirzepatide on the endometrium of endometrial cancer (EC). This is a pre-operative window clinical study.
- Obesity / overweightHigh blood pressureCOPD (chronic lung disease)
Feasibility of Semaglutide in Advanced Lung Disease
Testing whether semaglutide can be given safely to people with advanced lung disease
📍 University of Pennsylvania Perelman School of Medicine · Philadelphia, PA · Get directions →
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1.
- Obesity / overweight
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
Testing how safely cagrilintide is tolerated in people with obesity who can’t tolerate GLP-1
📍 Diablo Clinical Research, Inc. · Walnut Creek, CA · +10 more US sites · Get directions →
The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being tested) or Placebo (a treatment that has no active medicine in it).
- Obesity / overweightHeart / cardiovascular disease
Mechanisms of Semaglutide Therapy in Heart Failure Patients
Testing how semaglutide works in people with heart failure and obesity
📍 Greenstone Biosciences · Palo Alto, CA · +1 more US site · Get directions →
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells.
- Obesity / overweightHigh blood pressure
Understanding the Health Effect of a Bioactive Peptide From Egg: A Pilot Study
Testing how an egg-derived peptide affects health in people with obesity and high blood pressure
📍 University of Alberta · Edmonton, Alberta · Get directions →
Bioactive peptides derived from food proteins show potential for improving human health. One of such promising peptides is namely IRW made from egg white hydrolysate and composed of three peptides.
- Obesity / overweight
Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss
Testing whether adding a weight-loss medicine after stomach sleeve surgery helps people lose more
📍 Rush University Medical Center · Chicago, IL · Get directions →
This study examines whether adding tirzepatide-a medication that helps with weight loss-after sleeve gastrectomy surgery can help people lose more weight after the surgery; better improve conditions like Type 2 diabetes, high blood pressure, high cholesterol, and sleep apnea after surgery and; whether this causes more complications or side effects compared to surgery alone.
- Obesity / overweight💵 May compensate
Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
Testing whether tirzepatide affects liver fat markers in people with obesity
📍 University of New Mexico Health Sciences Center · Albuquerque, NM · Get directions →
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes and cardiovascular disease. Tirzepatide is a medication used to treat type 2 diabetes and obesity.